247 results
424B3
SYRE
Spyre Therapeutics Inc.
15 May 24
Prospectus supplement
4:06pm
. (“Pre-Merger Spyre”) (the “Asset Acquisition”); our ability to achieve the expected benefits or opportunities and related timing with respect … activities, efficacy and safety profile of our product candidates, potential therapeutic benefits and economic value of our product candidates, use
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
15 May 24
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
7:40am
ability to achieve the expected benefits or opportunities with respect to its pipeline of product candidates such as potential improved dosing regimens … over approved product candidates, Spyre’s preclinical and future clinical development activities, and the potential therapeutic benefits and economic
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
9 May 24
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:11pm
benefits and economic value of its product candidates, the timing and results of preclinical studies and clinical trials, including the
commencement
POS AM
yxewkt
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
424B3
vewarsaoxd d6xphtks5
18 Mar 24
Prospectus supplement
4:06pm
8-K
EX-99.1
kaclca
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
8-K
EX-10.1
m9vmum c79
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
8-K
EX-10.2
egoqolbyvwebrj78c
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
uni0nkd
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
gjq ap7b68
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
669b8ri65y7gf183
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm